

Alexander Zipprich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1630725/publications.pdf>

Version: 2024-02-01

47
papers

2,699
citations

279487

23
h-index

233125

45
g-index

51
all docs

51
docs citations

51
times ranked

2912
citing authors

#	ARTICLE	IF	CITATIONS
1	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
2	Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. <i>Journal of Hepatology</i> , 2013, 58, 45-50.	1.8	259
3	Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. <i>Liver International</i> , 2012, 32, 1407-1414.	1.9	215
4	Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. <i>Gastroenterology</i> , 2015, 149, 660-668.e1.	0.6	196
5	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	0.6	162
6	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
7	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	3.6	144
8	Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. <i>EBioMedicine</i> , 2018, 30, 138-147.	2.7	116
9	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112
10	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	1.8	97
11	Hepatic arterial flow volume and reserve in patients with cirrhosis: Use of intra-arterial Doppler and adenosine infusion. <i>Gastroenterology</i> , 1999, 116, 906-914.	0.6	83
12	Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition. <i>Hepatology</i> , 2009, 49, 185-194.	3.6	82
13	Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. <i>Gut</i> , 2010, 59, 963-968.	6.1	79
14	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. <i>Journal of Hepatology</i> , 2021, 74, 1362-1372.	1.8	74
15	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). <i>Journal of Hepatology</i> , 2021, 75, 1346-1354.	1.8	69
16	Impaired natural killer cell subset phenotypes in human obesity. <i>Immunologic Research</i> , 2018, 66, 234-244.	1.3	62
17	Functional significance of hepatic arterial flow reserve in patients with cirrhosis. <i>Hepatology</i> , 2003, 37, 385-392.	3.6	47
18	Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2516.	1.8	45

#	ARTICLE	IF	CITATIONS
19	The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. <i>Digestive and Liver Disease</i> , 2015, 47, 144-150.	0.4	43
20	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	2.4	42
21	Hemodynamics in the Isolated Cirrhotic Liver. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S254-S258.	1.1	35
22	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	1.8	28
23	Novel Î±-Oxoamide Advanced-Glycation Endproducts within the N^6-Carboxymethyl Lysine and N^6-Carboxyethyl Lysine Reaction Cascades. <i>Journal of Agricultural and Food Chemistry</i> , 2018, 66, 1898-1906.	2.4	24
24	Analysis of Advanced Glycation Endproducts in Rat Tail Collagen and Correlation to Tendon Stiffening. <i>Journal of Agricultural and Food Chemistry</i> , 2018, 66, 3957-3965.	2.4	24
25	Nitric oxide and vascular remodeling modulate hepatic arterial vascular resistance in the isolated perfused cirrhotic rat liver. <i>Journal of Hepatology</i> , 2008, 49, 739-745.	1.8	21
26	The role of hepatic arterial flow on portal venous and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G197-G202.	1.6	20
27	Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1179-1185.	0.8	18
28	Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial. <i>American Journal of Gastroenterology</i> , 2022, 117, 884-894.	0.2	18
29	Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis. <i>PLoS ONE</i> , 2017, 12, e0171260.	1.1	17
30	A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatory response in the CCl4-cirrhotic liver. <i>Liver International</i> , 2010, 30, 988-994.	1.9	16
31	The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis. <i>British Journal of Pharmacology</i> , 2018, 175, 2956-2967.	2.7	13
32	Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 785.	1.3	12
33	Hepatic Arterial Vasodilation Is Independent of Portal Hypertension in Early Stages of Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0121229.	1.1	11
34	Improvement of portal venous pressure in cirrhotic rat livers by systemic treatment with adipose tissue-derived mesenchymal stromal cells. <i>Cytotherapy</i> , 2017, 19, 1462-1473.	0.3	11
35	Daytime-Dependent Changes of Cannabinoid Receptor Type 1 and Type 2 Expression in Rat Liver. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1844.	1.8	11
36	Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00002.	1.3	10

#	ARTICLE	IF	CITATIONS
37	Effect of ETâ€A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: A proof of concept study. <i>Liver International</i> , 2021, 41, 554-561.	1.9	10
38	Mineralocorticoid receptors in nonâ€alcoholic fatty liver disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3165-3177.	2.7	8
39	Isolated bacterial infection without decompensation has no impact on survival of compensated patients with cirrhosis. <i>Liver International</i> , 2021, 41, 1370-1378.	1.9	7
40	The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. <i>Health Economics Review</i> , 2019, 9, 22.	0.8	6
41	Letter: improve survival! Place early preâ€emptive TIPSS in highâ€risk variceal bleeders. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 927-928.	1.9	5
42	Prognostic Factors in Compensated and Decompensated Cirrhosis. <i>Current Hepatology Reports</i> , 2014, 13, 171-179.	0.4	4
43	Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. <i>Hepatology Communications</i> , 2021, 5, 1755-1766.	2.0	3
44	Open or closed window: That is the question. <i>Journal of Hepatology</i> , 2021, 74, 485-486.	1.8	0
45	Portal Hypertension: Intrahepatic Mechanisms. , 2011, , 77-89.		0
46	(Pre)Primary Prophylaxis: Where Were We and Where Are We Heading?. , 2016, , 83-87.		0
47	Green tea extract to prevent colorectal adenomas in men and women: Results of the MIRACLE trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1551-1551.	0.8	0